Fundamental Analysis of Vanda Pharmaceuticals Inc - Growth / Value Index
VNDA - Valuation Highlights
Valuation Analysis
Price to Book Ratio is 0.546 indicating that it is undervalued.
Book Value in last 3 years is trending up
Tsr Value Index - Very Poor Score of 12.50
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -64.57 | 26.82 | -46.11 % | |
| Price to Book | 0.583 | 0.579 | -2.21 % | 0.582 |
| Price to Sales | 1.78 | 1.49 | 21.37 % | |
| Enterprise Value to EBITDA Multiple | -9.59 | 12.75 | -32.14 % |
VNDA - Profitability Highlights
Profitability Analysis
Gives Dividend Yield of 5.72 %
Company Earning excess return
Tsr Profitability Index - Very Poor Score of 6.88
EPS decline for last four quarters
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -0.903 | 2.16 | 81.47 % | -0.762 |
| Return On Asset | -0.757 | 1.82 | 83.46 % | -0.635 |
| Net Profit Margin | -2.75 | 5.56 | 125.23 % | -8.74 |
| Operating Profit Margin | -14.18 | -0.108 | -104.34 % | -19.46 |
| EBITDA Margin | -10.89 | 6.74 | 79.54 % | -19.46 |
Highlights
| Market Cap | 318926 K |
| Enterprise Value | 185503 K |
| Price/Book TTM | 0.583 |
| Outstanding Share | 58198.30 K |
| Float/ Outstanding Share | 89.77% |
| Dividend Yield | 5.72 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | -1.33 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 2.54 |
| Sloan Ratio | -0.0219 |
| Peter Lynch Fair Value | 0 |
VNDA - Growth Highlights
Growth Analysis
YoY Net Margin Jump by 125.23%
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 28.05
Annual sales in last 3 years is trending down
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 177604 K | 16.72 % | 4.84 % |
| Gross Profit | 174144 K | 15.57 % | 13.52 % |
| EBITDA | -19339.00 K | 49.52 % | 643.56 % |
| Net Profit | -4889.00 K | 87.57 % | 72.75 % |
| EPS | -0.085 | 85.58 % | NA |
VNDA - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 95.00
Debt to equity ratio has decreased and is lowest in last three years
Cash ratio of 4.43
Company's debt has increased with decreasing revenue.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0044 | -0.341 % | 0.0044 |
| Cash Ratio | 4.43 | -13.29 % | |
| Quick Ratio | 4.92 | -13.15 % | 4.69 |
| Shareholders Equity | 84.03 | 1.10 % | |
| Debt to EBITDA | 0.168 | -31.11 % |
Historical Valuation Ratios of Vanda Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Vanda Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Vanda Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Vanda Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)